Wall Street Zen Upgrades Medpace (NASDAQ:MEDP) to “Buy”

Medpace (NASDAQ:MEDP) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Several other research firms have also issued reports on MEDP. Cowen reaffirmed a “sell” rating on shares of Medpace in a report on Friday, October 24th. Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Truist Financial set a $555.00 target price on Medpace in a research report on Monday, October 27th. TD Cowen lifted their target price on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. Finally, Robert W. Baird set a $613.00 price target on shares of Medpace in a research report on Friday, October 24th. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Reduce” and an average target price of $491.27.

Medpace Price Performance

Shares of MEDP stock opened at $610.90 on Friday. The firm has a 50-day moving average of $582.73 and a 200-day moving average of $512.66. Medpace has a one year low of $250.05 and a one year high of $628.92. The company has a market cap of $17.21 billion, a P/E ratio of 42.72, a P/E/G ratio of 2.05 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the company earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts expect that Medpace will post 12.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Kevin M. Brady sold 3,000 shares of the business’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $590.35, for a total value of $1,771,050.00. Following the sale, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $3,542,100. The trade was a 33.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 668 shares of the stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the transaction, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. This represents a 0.10% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 387,925 shares of company stock valued at $233,386,647. 20.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Medpace

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quent Capital LLC purchased a new position in shares of Medpace in the third quarter valued at $25,000. Optiver Holding B.V. bought a new position in Medpace in the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. boosted its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Quarry LP purchased a new position in Medpace during the 3rd quarter valued at about $35,000. Finally, Employees Retirement System of Texas bought a new stake in shares of Medpace during the second quarter valued at about $36,000. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.